Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Standardised immunophenotypic analysis of myeloperoxidase in acute leukaemia

AE. Bras, Z. Osmani, V. de Haas, M. Jongen-Lavrencic, JG. Te Marvelde, CM. Zwaan, E. Mejstrikova, P. Fernandez, T. Szczepanski, A. Orfao, JJM. van Dongen, VHJ. van der Velden

. 2021 ; 193 (5) : 922-927. [pub] 20201107

Language English Country Great Britain

Document type Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21025642

Given its myeloid-restricted expression, myeloperoxidase (MPO) is typically used for lineage assignment (myeloid vs. lymphoid) during acute leukaemia (AL) diagnostics. In the present study, a robust flow cytometric definition for MPO positivity was established based on the standardised EuroFlow protocols, the standardised Acute Leukaemia Orientation Tube and 1734 multicentre AL cases (with confirmed assay stability). The best diagnostic performance was achieved by defining MPO positivity as ≥20% of the AL cells exceeding a lymphocyte-based threshold. The methodology employed should be applicable to any form of standardised flow cytometry.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025642
003      
CZ-PrNML
005      
20211026133628.0
007      
ta
008      
211013s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bjh.17210 $2 doi
035    __
$a (PubMed)33161592
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Bras, Anne E $u Laboratory Medical Immunology (LMI), Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
245    10
$a Standardised immunophenotypic analysis of myeloperoxidase in acute leukaemia / $c AE. Bras, Z. Osmani, V. de Haas, M. Jongen-Lavrencic, JG. Te Marvelde, CM. Zwaan, E. Mejstrikova, P. Fernandez, T. Szczepanski, A. Orfao, JJM. van Dongen, VHJ. van der Velden
520    9_
$a Given its myeloid-restricted expression, myeloperoxidase (MPO) is typically used for lineage assignment (myeloid vs. lymphoid) during acute leukaemia (AL) diagnostics. In the present study, a robust flow cytometric definition for MPO positivity was established based on the standardised EuroFlow protocols, the standardised Acute Leukaemia Orientation Tube and 1734 multicentre AL cases (with confirmed assay stability). The best diagnostic performance was achieved by defining MPO positivity as ≥20% of the AL cells exceeding a lymphocyte-based threshold. The methodology employed should be applicable to any form of standardised flow cytometry.
650    _2
$a akutní nemoc $7 D000208
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a průtoková cytometrie $x normy $7 D005434
650    _2
$a lidé $7 D006801
650    _2
$a imunofenotypizace $x normy $7 D016130
650    12
$a leukemie $x diagnóza $x enzymologie $x imunologie $7 D007938
650    _2
$a mužské pohlaví $7 D008297
650    12
$a nádorové proteiny $x krev $x imunologie $7 D009363
650    12
$a peroxidasa $x krev $x imunologie $7 D009195
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Osmani, Zgjim $u Laboratory Medical Immunology (LMI), Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
700    1_
$a de Haas, Valerie $u Dutch Childhood Oncology Group, Utrecht, the Netherlands $u Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands
700    1_
$a Jongen-Lavrencic, Mojca $u Department of Hematology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
700    1_
$a Te Marvelde, Jeroen G $u Laboratory Medical Immunology (LMI), Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
700    1_
$a Zwaan, C Michel $u Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands $u Department of Pediatric Oncology/Hematology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
700    1_
$a Mejstrikova, Ester $u CLIP-Childhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic
700    1_
$a Fernandez, Paula $u Institute for Laboratory Medicine, Kantonsspital Aarau AG, Aarau, Switzerland
700    1_
$a Szczepanski, Tomasz $u Department of Pediatric Hematology and Oncology, Zabrze, Medical University of Silesia (SUM), Katowice, Poland
700    1_
$a Orfao, Alberto $u Cancer Research Center (IBMCC-CSIC), Department of Medicine and Cytometry Service, University of Salamanca (USAL), Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain $u Centro de Investigaciόn Biomédicaen Red de Cáncer, Instituto Carlos III, Madrid, Spain
700    1_
$a van Dongen, Jacques J M $u Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands
700    1_
$a van der Velden, Vincent H J $u Laboratory Medical Immunology (LMI), Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
773    0_
$w MED00009374 $t British journal of haematology $x 1365-2141 $g Roč. 193, č. 5 (2021), s. 922-927
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33161592 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133634 $b ABA008
999    __
$a ok $b bmc $g 1714614 $s 1146149
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 193 $c 5 $d 922-927 $e 20201107 $i 1365-2141 $m British journal of haematology $n Br J Haematol $x MED00009374
LZP    __
$a Pubmed-20211013

Find record

Citation metrics

Archiving options